Improved Prognosis by Trastuzumab of Women With HER2-Positive Breast Cancer Compared With Those With HER2-Negative Disease - Reply to G. Ferretti et al

被引：1
作者：
Dawood, Shaheenah [1 ]
Giordano, Sharon H. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 20期
关键词：
ADJUVANT CHEMOTHERAPY; EXPRESSION; HER2; PLUS;
D O I：
10.1200/JCO.2010.28.3267
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E338 / E339
页数：2
相关论文
共 8 条
  • [1] Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
  • [2] Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
    Dawood, Shaheenah
    Broglio, Kristine
    Buzdar, Aman U.
    Hortobagyi, Gabriel N.
    Giordano, Sharon H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 92 - 98
  • [3] Improved Prognosis by Trastuzumab of Women With HER2-Positive Breast Cancer Compared With Those With HER2-Negative Disease
    Ferretti, Gianluigi
    Fabi, Alessandra
    Felici, Alessandra
    Papaldo, Paola
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : E337 - E337
  • [4] A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease
    Papaldo, P
    Fabi, A
    Ferretti, G
    Mottolese, M
    Cianciulli, AM
    Di Cocco, B
    Pino, MS
    Carlini, P
    Di Cosimo, S
    Sacchi, I
    Sperduti, I
    Nardoni, C
    Cognetti, F
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (04) : 630 - 636
  • [5] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ
    Procter, M
    Leyland-Jones, B
    Goldhirsch, A
    Untch, M
    Smith, I
    Gianni, L
    Baselga, J
    Bell, R
    Jackisch, C
    Cameron, D
    Dowsett, M
    Barrios, CH
    Steger, G
    Huang, CS
    Andersson, M
    Inbar, M
    Lichinitser, M
    Láng, I
    Nitz, U
    Iwata, H
    Thomssen, C
    Lohrisch, C
    Suter, TM
    Ruschoff, J
    Süto, T
    Greatorex, V
    Ward, C
    Straehle, C
    McFadden, E
    Dolci, MS
    Gelber, RD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) : 1659 - 1672
  • [6] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Romond, EH
    Perez, EA
    Bryant, J
    Suman, VJ
    Geyer, CE
    Davidson, NE
    Tan-Chiu, E
    Martino, S
    Paik, S
    Kaufman, PA
    Swain, SM
    Pisansky, TM
    Fehrenbacher, L
    Kutteh, LA
    Vogel, VG
    Visscher, DW
    Yothers, G
    Jenkins, RB
    Brown, AM
    Dakhil, SR
    Mamounas, EP
    Lingle, WL
    Klein, PM
    Ingle, JN
    Wolmark, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) : 1673 - 1684
  • [7] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
    Slamon, DJ
    Leyland-Jones, B
    Shak, S
    Fuchs, H
    Paton, V
    Bajamonde, A
    Fleming, T
    Eiermann, W
    Wolter, J
    Pegram, M
    Baselga, J
    Norton, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) : 783 - 792
  • [8] Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
    Sorlie, T
    Perou, CM
    Tibshirani, R
    Aas, T
    Geisler, S
    Johnsen, H
    Hastie, T
    Eisen, MB
    van de Rijn, M
    Jeffrey, SS
    Thorsen, T
    Quist, H
    Matese, JC
    Brown, PO
    Botstein, D
    Lonning, PE
    Borresen-Dale, AL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) : 10869 - 10874
1